Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Health Outcomes and Costs (HOC) in Lung Cancer (LC) (HOC-LC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02363101
Recruitment Status : Unknown
Verified March 2015 by Carlos Gil Moreira Ferreira, Instituto Nacional de Cancer, Brazil.
Recruitment status was:  Not yet recruiting
First Posted : February 13, 2015
Last Update Posted : March 4, 2015
Sponsor:
Collaborator:
Instituto Nacional de Cardiologia de Laranjeiras
Information provided by (Responsible Party):
Carlos Gil Moreira Ferreira, Instituto Nacional de Cancer, Brazil

Brief Summary:
The purpose of this study is to evaluate the costs, health-related quality of life and preference values from lung cancer patients assisted in a Brazilian public health care unit.

Condition or disease
Lung Cancer

Detailed Description:

The costs will be assessed by micro-costing approach. All procedures involved in lung cancer at diagnosis, staging, treatment and best supportive care will be assessed.

The health-related quality of life will be assessed by EORTC-QLQ-C30, EQ-5D and EORTC-QLQ-LC13 in all different stages of lung cancer.

An utility measure will be considered. The preference values will be assessed via discrete choice experiment. Two scenarios will be designed and the lung cancer patients will be asked about the preferences.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Time Perspective: Cross-Sectional
Official Title: Health Outcomes and Costs (HOC) in Brazilian Public Health Care System - The HOC Study in Lung Cancer
Study Start Date : March 2015
Estimated Primary Completion Date : March 2016
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer




Primary Outcome Measures :
  1. Direct costs [ Time Frame: one year ]
    Direct costs related to each procedure involved on lung cancer

  2. HRQoL [ Time Frame: up to 30 days after the procedure ]
  3. Preference values [ Time Frame: cross sectional ]
    Evaluate preference values in hypothetic scenarios



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Lung cancer patients from Instituto Nacional de Câncer during one year.
Criteria

Inclusion Criteria:

  • Clinical diagnosis of lung cancer disease
  • Able to understand the overall concept of study and sign the written informed consent

Exclusion Criteria:

  • Illiterate
  • Visible cognitive impaired
  • Non-primary lung tumor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02363101


Contacts
Layout table for location contacts
Contact: Luciene Schluckebier 552132076660 lschluckebier@inca.gov.br
Contact: Alessandra Marins 55 21 32076569 amarins@inca.gov.br

Locations
Layout table for location information
Brazil
INCA - Instituto Nacional de Câncer Not yet recruiting
Rio de Janeiro, Brazil
Contact: Luciene Schluckebier    55 21 32076660    lschluckebier@inca.gov.br   
Contact: Alessandra Marins    55 21 32076569    amarins@inca.gov.br   
Sponsors and Collaborators
Instituto Nacional de Cancer, Brazil
Instituto Nacional de Cardiologia de Laranjeiras
Investigators
Layout table for investigator information
Principal Investigator: Carlos Gil Ferreira National Cancer Institute, France
Study Director: Luciene Schluckebier National Cancer Institute, France
Study Chair: Marisa Santos INC
Study Chair: Bruna Carvalho National Cancer Institute, France
Study Chair: Pedro Masson National Cancer Institute, France
Study Chair: Andréa Monteiro INC
Study Chair: Bruna Medeiros INC
Study Chair: Kátia Senna INC
Study Chair: Márcia Gisele INC

Layout table for additonal information
Responsible Party: Carlos Gil Moreira Ferreira, MD PHD, Instituto Nacional de Cancer, Brazil
ClinicalTrials.gov Identifier: NCT02363101     History of Changes
Other Study ID Numbers: INCA012015
First Posted: February 13, 2015    Key Record Dates
Last Update Posted: March 4, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases